ISOSORBIDE

/static/temp/default.svg

Search structure


Trade Names	ISMOTIC
Synonyms	1,4:3,6-dianhydro-d-glucitol AT-101 D-glucitol, 1,4:3,6-dianhydro- Ismotic Isobide Isosorbide NSC-40725
Status
Molecule Category	Free-form
UNII	WXR179L51S
EPA CompTox	DTXSID5046196


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	KLDXJTOLSGUMSJ-JGWLITMVSA-N
Smiles	O[C@@H]1CO[C@H]2[C@@H]1OC[C@@H]2O
InChI	InChI=1S/C6H10O4/c7-3-1-9-6-4(8)2-10-5(3)6/h3-8H,1-2H2/t3-,4+,5-,6-/m1/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C6H10O4
Molecular Weight	146.14
AlogP	-1.49
Hydrogen Bond Acceptor	4.0
Hydrogen Bond Donor	2.0
Number of Rotational Bond	0.0
Polar Surface Area	58.92
Molecular species	NEUTRAL
Aromatic Rings	0.0
Heavy Atoms	10.0

Assay Description	Organism	Bioactivity	Reference
Antiplatelet aggregation activity in rabbit platelets assessed as inhibition of ADP-induced platelet aggregation at 1 mM incubated for 5 mins prior to ADP-challenge measured within 5 mins by Born's turbidimetric analysis relative to control	Oryctolagus cuniculus	6.94 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging	Homo sapiens	-5.34 %
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate	Severe acute respiratory syndrome coronavirus 2	4.695 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	-0.06 %		Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	-0.06 %

Cross References

Resources	Reference
ChEBI	6060
ChEMBL	CHEMBL1200660
DrugBank	DB09401
DrugCentral	1501
FDA SRS	WXR179L51S
PubChem	12597
SureChEMBL	SCHEMBL15495
ZINC	ZINC000018284778

CONTENTS

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).